Incretin Atlas › Trials › Phase 3 monotherapy (NCT04504370)
Phase 3 monotherapy (NCT04504370)
PB-119 · t2d
Design
- Molecule(s)
- PB-119
- Population
- t2d
- Official title
- Safety and Efficacy of Pegylated Exenatine Injection (PB-119) in Drug-naïve T2DM Subjects
- Sponsor
- PegBio Co., Ltd.
- Phase
- 3
- Registry status
- completed · 2020-04 → 2022-03
- Participants
- 273
- Duration
- 24 weeks
- Registry
- NCT04504370
Results by arm
| Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 150 μg QW | t2d china | 24 | 137 | — | — | −1.4 vs −0.6 | 2.2 | 4.4 vs 7.4 | 8.0 vs 0.7 | 5.8 vs 0.0 | 6.6 vs 1.5 | — | press release |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Verbatim quotes from the source (6)
- 150 μg QW · hba1c · publication
the least squares mean (LSM) change from baseline in HbA1c was −1.36% (95% CI 1.52 to −1.20)
- 150 μg QW · nausea · Table 4 (safety set; double-blind 24-week period; Visepegena
Nausea 11 (8.0) 32 1 (0.7)
- 150 μg QW · vomiting · Table 4 (safety set; double-blind 24-week period; Visepegena
Vomiting 8 (5.8) 14 0 (0.0)
- 150 μg QW · ae_dc · publication
The common cause of treatment discontinuation was AE in three (2.2%) participants of the visepegenatide group
- 150 μg QW · disc_any · publication
Six (4.4%) participants received visepegenatide and 10 (7.4%) participants received placebo discontinued the treatment in the double-blinded treatment period.
- 150 μg QW · sae · Table 4 (safety set; double-blind 24-week period; Visepegena
Serious Adverse Events (SAEs) 9 (6.6) 10 2 (1.5)
Primary sources
- PegBio. Efficacy and safety of visepegenatide (PB-119) as monotherapy in T2DM: phase 3 RCT. Lancet Reg Health West Pac 2024;47:101101 [publication]. 2024-06. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC11214404/
- ClinicalTrials.gov NCT04504370
How to cite this page
Medical Adviser's Group. Incretin Atlas: Phase 3 monotherapy (NCT04504370). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/phase-3-monotherapy/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.